Paroxysmal exercise-induced dystonia within the phenotypic spectrum ofECHS1deficiency
- 19 April 2016
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 31 (7) , 1041-1048
Abstract
Background ECHS1 encodes a mitochondrial enzyme involved in the degradation of essential amino acids and fatty acids. Recently, ECHS1 mutations were shown to cause a new severe metabolic disorder presenting as Leigh or Leigh-like syndromes. The objective of this study was to describe a family with 2 siblings affected by different dystonic disorders as a resulting phenotype of ECHS1 mutations. Methods Clinical evaluation, MRI imaging, genome-wide linkage, exome sequencing, urine metabolite profiling, and protein expression studies were performed. Results The first sibling is 17 years old and presents with generalized dystonia and severe bilateral pallidal MRI lesions after 1 episode of infantile subacute metabolic encephalopathy (Leigh-like syndrome). In contrast, the younger sibling (15 years old) only suffers from paroxysmal exercise-induced dystonia and has very mild pallidal MRI abnormalities. Both patients carry compound heterozygous ECHS1 mutations: c.232G>T (predicted protein effect: p.Glu78Ter) and c.518C>T (p.Ala173Val). Linkage analysis, exome sequencing, cosegregation, expression studies, and metabolite profiling support the pathogenicity of these mutations. Expression studies in patients' fibroblasts showed mitochondrial localization and severely reduced levels of ECHS1 protein. Increased urinary S-(2-carboxypropyl)cysteine and N-acetyl-S-(2-carboxypropyl)cysteine levels, proposed metabolic markers of this disorder, were documented in both siblings. Sequencing ECHS1 in 30 unrelated patients with paroxysmal dyskinesias revealed no further mutations. Conclusions The phenotype associated with ECHS1 mutations might be milder than reported earlier, compatible with prolonged survival, and also includes isolated paroxysmal exercise-induced dystonia. ECHS1 screening should be considered in patients with otherwise unexplained paroxysmal exercise-induced dystonia, in addition to those with Leigh and Leigh-like syndromes. Diet regimens and detoxifying agents represent potential therapeutic strategies. © 2016 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Stichting ParkinsonFonds (The Netherlands)
- Slovak Scientific Grant Agency (VEGA 1/0724/15)
This publication has 24 references indexed in Scilit:
- Familial paroxysmal nonkinesigenic dyskinesia: Clinical and genetic analysis of a Taiwanese familyJournal of the Neurological Sciences, 2012
- Mutations in PRRT2 result in paroxysmal dyskinesias with marked variability in clinical expressionJournal of Medical Genetics, 2011
- Paroxysmal dyskinesiasMovement Disorders, 2011
- Enzymology of the branched‐chain amino acid oxidation disorders: the valine pathwayJournal of Inherited Metabolic Disease, 2010
- A general introduction to the biochemistry of mitochondrial fatty acid β‐oxidationJournal of Inherited Metabolic Disease, 2010
- A Family With Paroxysmal Nonkinesigenic Dyskinesia: Genetic and Treatment IssuesPediatric Neurology, 2009
- GLUT1 gene mutations cause sporadic paroxysmal exercise‐induced dyskinesiasMovement Disorders, 2009
- Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1Brain, 2008
- GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leakJournal of Clinical Investigation, 2008
- Genotype–phenotype correlation of paroxysmal nonkinesigenic dyskinesiaNeurology, 2007